Quarterly Statement of Operations Information (Unaudited)

12 Months Ended

Sep. 29, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Statement of Operations Information (Unaudited)

The following table presents a summary of quarterly results of operations for fiscal 2018 and 2017:



	2018
	First Quarter		Second Quarter			Third Quarter		Fourth Quarter
Total revenue	$	791.1	$	789.3		$	824.0	$	813.5
Gross profit	424.5		415.1			436.0		421.1
Net income (loss) (1)	406.7		(681.4		)	112.9		50.5
Diluted net income (loss) per common share	$	1.45	$	(2.46	)	$	0.41	$	0.18



	2017
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
Total revenue	$	734.4	$	715.4	$	806.1	$	802.9
Gross profit	404.8		388.7		409.6		417.9
Net income (2)	86.5		526.8		59.5		82.7
Diluted net income per common share	$	0.30	$	1.84	$	0.21	$	0.29

(1)

Net income in the first quarter of fiscal 2018 included the impact of implementing tax reform, which resulted in a provisional net tax benefit of $329.2 million. Net loss in the second quarter of fiscal 2018 included a goodwill impairment charge of $685.7 million, an in-process research and development intangible asset charge of $46.0 million and a debt extinguishment loss of $44.9 million. Net income in the fourth quarter of fiscal 2018 included a litigation settlement charge of $34.8 million.


(2)	Net income in the second quarter of fiscal 2017 included a gain on the sale of the blood screening business of $899.7 million and acquisition transaction expenses of $19.4 million.